Laurus Labs Ltd logo

Laurus Labs Ltd

LAURUSLABS NSE

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

AI Verdict: HOLD Confidence: 4%

Laurus Labs shows strong profit recovery with TTM profit growth of 216% and impressive stock CAGR of 117% over 1 year, but the stock trades at an expensive PE of 83.1x and 14.4x book value with weak 5-year sales CAGR of just 7%. The divided analyst consensus (38% buy, 38% sell) reflects genuine uncertainty at current valuations.

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹78,301 Cr
Volatility
Moderate
P/E Ratio
88.09
EBITDA
₹1,833 Cr
Return on Equity
4.09%
Debt to Equity
0.54
Book Value
₹98.11
EPS
₹2.75
52W High
₹1,492.6
52W Low
₹663.05

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 19.0%

Weaknesses

4
  • Stock is trading at 14.8 times its book value
  • The company has delivered a poor sales growth of 7.19% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
22.01% ↗
Net Income Growth
151.10% ↗
Cash Flow Change
169.84% ↗
ROE
112.73% ↗
ROCE
62.83% ↗
EBITDA Margin (Avg.)
32.87% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk high

Laurus Labs shows strong profit recovery with TTM profit growth of 216% and impressive stock CAGR of 117% over 1 year, but the stock trades at an expensive PE of 83.1x and 14.4x book value with weak 5-year sales CAGR of just 7%. The divided analyst consensus (38% buy, 38% sell) reflects genuine uncertainty at current valuations.

Bull Case 8
  • TTM compounded profit growth of 216% signals a powerful earnings recovery cycle underway
  • Stock has delivered 117% returns over the past 1 year, reflecting strong momentum and re-rating
  • ROE has improved to 18% in the last year from a 3-year average of 10%, indicating operational turnaround
  • TTM sales growth of 23% marks a significant acceleration versus the 3-year CAGR of just 4%
  • 10-year compounded profit CAGR of 21% demonstrates long-term earnings compounding ability
  • Company maintains a healthy dividend payout ratio of 19.0%, providing some income support
  • Market cap of Rs 74,786 Cr provides reasonable liquidity and institutional participation
  • 5-year ROE of 15% and 10-year ROE of 17% show structural profitability in the business model
Bear Case 8
  • PE ratio of 83.1x is extremely elevated, pricing in near-perfect execution with minimal margin of safety
  • Stock trades at 14.4x book value, far above pharma sector averages of 3-5x, leaving significant downside risk
  • 5-year compounded sales growth of only 7% is poor for a company commanding such premium multiples
  • 5-year compounded profit growth is negative at -2%, showing the recent recovery follows years of earnings decline
  • 3-year ROE of just 10% is below cost of equity, indicating inadequate shareholder value creation over that period
  • Analyst consensus is sharply divided with 38.46% recommending sell — unusual bearish sentiment for a mid-large cap pharma name
  • Dividend yield of only 0.15% offers negligible income cushion against potential capital loss at current valuations
  • Company might be capitalizing interest costs, which could overstate reported profitability and asset quality

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Headwinds 2
  • Consensus target implies 14% downside Jun 05

    Analyst consensus target price of ₹1,245 represents a 13.93% downside from current trading level of ₹1,446.80, suggesting stretched valuations.

  • Elevated PE ratio at 100x May 27

    Stock trading at a PE ratio of 100.13 on trailing twelve months earnings ending March 2026, indicating premium valuation that leaves little room for disappointment.

Positives 4
  • CDMO segment up 58% YoY Jun 05

    Q2FY26 consolidated revenue grew 31.4% YoY to ₹15,696 million, beating estimates by 15%, with CDMO revenues up 58% YoY and EBITDA margins improving 979 bps to 24.4%.

  • Stock surged 40% in 6 months Jun 05

    Laurus Labs hit new highs at ₹1,449.90, gaining 40% over six months and 23% in the past month alone, sharply outperforming the BSE Sensex which fell 14%.

  • 127% return in one year May 27

    Stock delivered 127.6% gains over the last year versus a 3.32% decline in NIFTY and 15.48% fall in Nifty Pharma index, with three consecutive sessions of gains.

  • Brokerages maintain positive outlook Jun 05

    Kotak Institutional Equities highlights improving CDMO visibility and margin expansion from evolving product mix; Choice notes profitability growth may be slower due to elevated capex.

Neutral 5
  • Large institutional block trades Jun 19

    Two block trades recorded on NSE — ₹24.91 crores (1.8 lakh shares at ₹1,382.40) on Jun 19 and ₹81.12 crores (5.86 lakh shares at ₹1,383.40) on Jun 2, reflecting institutional activity.

  • Investor meetings with top banks Jun 08

    Laurus Labs scheduled investor meetings with Goldman Sachs (Jun 12), BofA, and Macquarie in Hyderabad in June 2026; no UPSI to be shared.

  • Record date set for dividend Jun 06

    June 10, 2026 fixed as record date for dividend payment, subject to shareholder approval at the 21st AGM scheduled for July 2, 2026.

  • BRSR filed for FY26 Jun 08

    Business Responsibility and Sustainability Report filed showing exports at 62.14% of turnover and zero safety incidents for FY26.

  • Promoters confirm no encumbrance Jun 06

    Promoter group declared no new share encumbrances in FY26 via disclosure submitted to exchanges on April 7, 2026.

TL;DR: Laurus Labs is delivering strong operational momentum with 58% CDMO growth, significant margin expansion, and consistent earnings beats that have driven the stock up 127% in a year. The key risk is valuation — trading at 100x PE with analyst consensus implying ~14% downside, leaving the stock priced for near-perfect execution. Institutional interest remains high as evidenced by block trades and active investor engagement. The trend is firmly positive on fundamentals, but stretched valuations warrant caution if growth disappoints.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
1,381
1,182
1,224
1,195
1,440
1,195
1,224
1,415
1,720
1,570
1,653
1,778
1,812
Expenses
1,095
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
1,298
1,299
Operating Profit
286
167
188
181
241
171
178
285
421
382
403
480
512
OPM %
21%
14%
15%
15%
17%
14%
15%
20%
24%
24%
24%
27%
28%
Other Income
2
4
2
2
19
3
5
9
59
10
27
6
12
Interest
53
39
42
51
50
49
53
58
56
52
40
39
40
Depreciation
87
91
93
98
102
106
108
106
110
117
120
121
122
PBT
147
41
54
35
107
18
23
131
312
224
270
327
361
Tax %
27%
30%
27%
27%
30%
34%
22%
31%
25%
28%
28%
22%
22%
Net Profit
105
27
37
23
75
13
20
93
233
162
194
252
282
EPS in Rs
1.91
0.46
0.69
0.43
1.4
0.23
0.37
1.71
4.33
3.02
3.61
4.66
5.17
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
1,327
1,778
1,905
2,056
2,292
2,832
4,814
4,936
6,041
5,041
5,554
6,813
Expenses
1,126
1,415
1,497
1,642
1,935
2,266
3,262
3,512
4,448
4,261
4,499
5,028
Operating Profit
200
362
408
414
357
565
1,552
1,424
1,592
779
1,055
1,785
OPM %
15%
20%
21%
20%
16%
20%
32%
29%
26%
15%
19%
26%
Other Income
34
4
32
29
15
5
23
14
6
24
75
47
Interest
106
111
100
80
88
90
68
102
165
183
216
171
Depreciation
62
86
106
125
164
187
205
251
324
385
430
480
PBT
67
169
234
237
120
294
1,301
1,084
1,109
236
484
1,182
Tax %
-2%
21%
19%
29%
22%
13%
24%
23%
28%
29%
27%
25%
Net Profit
68
134
190
168
94
255
984
832
793
162
358
890
EPS in Rs
8.81
16.97
3.6
3.16
1.76
4.77
18.33
15.4
14.67
2.98
6.64
16.46
Div. Payout %
0%
2%
8%
9%
17%
10%
11%
13%
14%
27%
18%
12%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
106
106
106
107
107
107
108
108
108
108
Reserves
640
774
1,225
1,377
1,452
1,663
2,490
3,244
3,930
4,003
4,365
5,192
Borrowings
888
1,094
842
980
1,036
1,079
1,482
1,777
2,015
2,577
2,764
2,518
Other Liabilities
345
339
481
554
737
901
1,671
1,840
1,608
1,699
2,099
2,693
Total Liabilities
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,652
3,409
3,890
4,123
4,371
CWIP
110
70
143
163
110
67
362
813
551
423
458
773
Investments
7
7
3
3
3
3
3
31
50
124
233
309
Other Assets
970
1,126
1,277
1,369
1,589
1,953
3,214
3,472
3,651
3,950
4,521
5,058
Total Assets
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-65
182
332
342
298
347
733
911
994
666
602
1,624
Investing
-397
-312
-289
-384
-253
-221
-941
-914
-997
-822
-680
-1,086
Financing
486
103
-54
42
-45
-128
255
30
-27
250
39
-525
Net Cash Flow
24
-27
-10
1
0
-1
47
27
-30
93
-39
13
Free Cash Flow
-447
-144
55
-49
44
125
49
34
6
-10
61
560
CFO/OP
-24
59
94
98
91
68
62
77
80
99
70
107
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
78
91
109
101
113
102
99
100
96
120
132
115
Inventory Days
210
176
186
201
201
234
266
293
222
277
285
317
Days Payable
102
90
96
107
144
159
199
146
94
158
141
170
Cash Conversion Cycle
186
178
199
195
170
177
166
247
224
240
276
263
Working Capital Days
0
19
3
-11
6
15
43
43
59
42
43
58
ROCE %
14%
16%
16%
14%
8%
14%
40%
26%
23%
7%
9%
18%

Shareholding Pattern

As of Mar 2026
Promoters 27.49%
FIIs 25.82%
Public 21.24%
DIIs 13.97%
Others 11.47%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
27.45%
27.30%
27.30%
27.27%
27.27%
27.27%
27.27%
27.20%
27.20%
27.20%
27.20%
27.19%
27.19%
27.18%
27.18%
27.62%
27.62%
27.59%
27.59%
27.49%
27.49%
FIIs
0.00%
0.04%
0.04%
0.02%
0.02%
0.02%
0.00%
0.02%
0.02%
0.00%
0.00%
0.00%
25.97%
25.67%
26.08%
25.56%
25.52%
25.70%
26.16%
26.52%
25.82%
DIIs
2.06%
2.40%
2.11%
2.77%
3.51%
4.77%
8.98%
9.51%
9.74%
10.14%
10.71%
10.77%
11.77%
13.56%
13.05%
12.74%
11.77%
11.94%
11.73%
12.43%
13.97%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
34.17%
34.18%
32.91%
32.87%
31.15%
28.42%
27.96%
28.95%
28.49%
28.26%
26.49%
25.01%
23.95%
22.68%
22.67%
22.72%
23.65%
23.12%
23.33%
22.64%
21.24%
Others
36.32%
36.07%
37.65%
37.08%
38.05%
39.53%
35.80%
34.32%
34.55%
34.39%
35.60%
37.03%
11.12%
10.91%
11.03%
11.36%
11.44%
11.65%
11.18%
10.92%
11.47%
No. of Shareholders
2,35,836
2,99,257
3,94,053
4,67,419
4,27,465
4,07,186
3,90,695
4,23,931
4,18,615
4,17,977
4,02,640
3,82,880
3,56,830
3,24,059
3,09,063
2,92,214
2,92,905
2,80,223
2,83,678
2,80,756
2,92,281

Documents

Frequently Asked Questions about Laurus Labs Ltd

What does Laurus Labs Ltd do?
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They a...
Where is Laurus Labs Ltd (LAURUSLABS) listed?
Laurus Labs Ltd is listed on the Indian stock exchanges. It is listed on NSE: LAURUSLABS and BSE: 540222. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Laurus Labs Ltd belong to?
Laurus Labs Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Laurus Labs Ltd?
Laurus Labs Ltd has a market capitalisation of approximately ₹78300.80 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Laurus Labs Ltd?
The Price-to-Earnings (PE) ratio of Laurus Labs Ltd is 88.09. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Laurus Labs Ltd?
Over the past 52 weeks, Laurus Labs Ltd has traded between a low of ₹663.05 and a high of ₹1,492.6. This range helps investors understand the stock's price volatility and recent trading levels.
Does Laurus Labs Ltd pay dividends?
Yes, Laurus Labs Ltd has a dividend yield of 0.14%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Laurus Labs Ltd?
Laurus Labs Ltd has a Return on Equity (ROE) of 4.09%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Laurus Labs Ltd on Tapetide?
On Tapetide, you can view Laurus Labs Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Website lauruslabs.com
CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
Employees 6,167
Listed 2016-12-19
Face Value ₹ 2
Issued Size 53,98,56,582

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List